Brenda Goodwin
Endocrinology, Diabetes & Metabolism · Chattanooga, TNNPI 1033183462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TN, where the typical reported total is $2,871.
Across 119 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$395
- BETA Bionics, Inc.$245
- Bayer$222
- Xeris Pharmaceuticals, Inc.$201
- Novo Nordisk$199
- Corcept Therapeutics$137
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,61097%
- Education$743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 20 | $395 |
| BETA Bionics, Inc. | 5 | $245 |
| Bayer | 10 | $222 |
| Xeris Pharmaceuticals, Inc. | 10 | $201 |
| Novo Nordisk | 11 | $199 |
| Corcept Therapeutics | 4 | $137 |
| Tandem Diabetes Care, Inc. | 5 | $136 |
| AbbVie | 6 | $132 |
| Cequr Corporation | 3 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $118 |
| Abbott | 6 | $113 |
| Boehringer Ingelheim | 4 | $74 |
| Ascendis Pharma Endocrinology Inc | 3 | $64 |
| Medtronic | 3 | $61 |
| Kyowa Kirin, Inc. | 3 | $58 |
| Boston Scientific | 2 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| IBSA Pharma Inc. | 1 | $35 |
| OPKO Pharmaceuticals, LLC | 2 | $34 |
| Amgen | 1 | $28 |
| Dexcom, Inc. | 1 | $26 |
| Alfasigma USA, Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Bigfoot Biomedical Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| Merck | 1 | $14 |
| Sequel Med Tech, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,685 in reported general payments places this provider in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $98,808 |
| MounjaroTirzepatide | 71 | $71,882 |
| JardianceEmpagliflozin | 51 | $71,554 |
| TrulicityDulaglutide | 31 | $41,743 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $37,282 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $35,961 |
| FarxigaDapagliflozin Propanediol | 23 | $20,817 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $18,138 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $7,773 |
| Novolog FlexpenInsulin Aspart | 40 | $7,022 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $6,965 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 34 | $6,955 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $6,417 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,122 |
| SynthroidLevothyroxine Sodium | 40 | $3,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $395 | $114,882114 claims |
| Novo NordiskOzempic | $199 | $98,80889 claims |
| Boehringer IngelheimJardiance | $74 | $71,55451 claims |
| AbbVieSynthroid | $132 | $3,64940 claims |
| Sanofi-aventis U.S. LLCLantus | $118 | $2,06920 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $1,126106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Chattanooga
- David HuffmanChattanooga$163K
- Asma KhanChattanooga$17K
- Abhinaya JawaharChattanooga$8K
- Matthew HollieChattanooga$5K
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.